Literature DB >> 15698939

Cytokines and inflammatory mediators in cystic fibrosis.

J M Courtney1, M Ennis, J S Elborn.   

Abstract

Airway disease in cystic fibrosis (CF) is characterised by a continuous cycle of chronic infection and inflammation dominated by a neutrophilic infiltrate. This inflammation is characterised by an increased production of pro-inflammatory cytokines in the lung. The relationship between the abnormal CFTR gene product and the development of inflammation and progression of lung disease in CF is not fully understood. This review article studied the mechanisms of pulmonary inflammation in CF, the profiles of cytokines and inflammatory mediators in the lung in CF, the mechanisms that predispose to chronic Pseudomonas aeruginosa infection, cytokine involvement in diseases other than CF and reviewed current therapeutic strategies for CF. Imbalances of cytokine secretion are now better understood due to recent advances in understanding CF at a molecular level and it is increasingly thought that the normal inflammatory process is deranged in CF early in the course of the disease and may occur in the absence of detectable infection. However, the relationship between this unbalanced cytokine production, the mutations in CFTR and its actual consequence for pathogenesis need further investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15698939     DOI: 10.1016/j.jcf.2004.06.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  36 in total

1.  Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis.

Authors:  Éanna Forde; André Schütte; Emer Reeves; Catherine Greene; Hilary Humphreys; Marcus Mall; Deirdre Fitzgerald-Hughes; Marc Devocelle
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 2.  The role of microRNAs in chronic respiratory disease: recent insights.

Authors:  Lindsay R Stolzenburg; Ann Harris
Journal:  Biol Chem       Date:  2018-02-23       Impact factor: 3.915

Review 3.  TGFβ as a therapeutic target in cystic fibrosis.

Authors:  Elizabeth L Kramer; John P Clancy
Journal:  Expert Opin Ther Targets       Date:  2017-12-13       Impact factor: 6.902

4.  Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  J Cyst Fibros       Date:  2019-04-26       Impact factor: 5.482

5.  A secretory leukocyte protease inhibitor variant with improved activity against lung infection.

Authors:  N Camper; A M A Glasgow; M Osbourn; D J Quinn; D M Small; D T McLean; F T Lundy; J S Elborn; P McNally; R J Ingram; S Weldon; C C Taggart
Journal:  Mucosal Immunol       Date:  2015-09-16       Impact factor: 7.313

6.  Quorum-sensing inhibition abrogates the deleterious impact of Pseudomonas aeruginosa on airway epithelial repair.

Authors:  Manon Ruffin; Claudia Bilodeau; Émilie Maillé; Shantelle L LaFayette; Geoffrey A McKay; Nguyen Thu Ngan Trinh; Trevor Beaudoin; Martin-Yvon Desrosiers; Simon Rousseau; Dao Nguyen; Emmanuelle Brochiero
Journal:  FASEB J       Date:  2016-05-13       Impact factor: 5.191

Review 7.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

8.  Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor.

Authors:  Nina Reiniger; Martin M Lee; Fadie T Coleman; Christopher Ray; David E Golan; Gerald B Pier
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

Review 9.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

10.  Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.

Authors:  Misagh Alipour; Zacharias E Suntres; Majed Halwani; Ali O Azghani; Abdelwahab Omri
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.